Navigation Links
Vermillion Sharpens Focus and Streamlines Operations in 2012
Date:1/4/2012

AUSTIN, Texas, Jan. 4, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focusing on cancer and cardiology, announced a plan to streamline its organization and extend its cash runway.

Vermillion's management and Board of Directors have reviewed the company's first complete year of commercialization progress and put in place a plan aimed to leverage the milestones achieved in 2011.   

With approximately $22.5 million in cash as of December 31, 2011, the company has commenced a restructuring program to reduce headcount and other expenses. The company intends to reduce cash-based operating expenses to approximately $12 million in 2012. Cash utilization will likely range between $3-4 million in the first quarter of 2012 as the company concludes remaining claim activities related to its emergence from Chapter 11.

  1. Operating activities in 2012 will concentrate on supporting Quest's OVA1® commercialization. This will involve building market awareness for OVA1, expanding payer coverage, supporting Quest's reimbursement activities, and growing test volumes.
  2. Product development activities will focus on advancing OVA2™, a next generation test for ovarian cancer, and VASCLIR® for the diagnosis of peripheral artery disease which will involve publication support for the positive results achieved in the VASCLIR intended use study, as well as further development of the company's IP portfolio.
  3. The company has begun to explore partnerships for its product pipeline, with the goal of accelerating development and bringing additional resources to the commercial effort.

"Given the short-term challenges in both our business and the industry, the company will sharpen its operational focus resulting in an extended runway," said Gail Page, Vermillion's chief executive officer. "The company
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
2. Vermillion Reports Results for the Second Quarter 2011
3. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
4. Vermillion Announces Joining Russell Microcap® Index
5. Vermillion Announces Notice of Allowance for Alzheimer Patent
6. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
7. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
8. Stephens Initiates Coverage on Vermillion
9. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
10. Vermillion Announces Issuance of European Patent
11. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... In her thought ... transports the reader to a not-so-distant future faced with an Ebola pandemic that is ... who overcomes personal tragedy to enter the world of counterterrorism, and who continues to ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... joint disease. , Equine cervical facet joint problems can be caused by ... and can cause impingement of nerve roots or of the spinal cord itself. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Leading CEOs, CSOs, CMOs, ... management space join prominent academics and key investors for Neuro Advance Boston, October ... in Boston. , Neuro Advance Boston focuses on the latest developments and ...
(Date:9/1/2015)... , Sept. 1, 2015   Medfusion, Inc., ... the relationship between doctors and patients, today announced ... Durham, N.C. -based venture capital firms.   ... business association with Bull City Venture Partners and ... Medfusion Founder and Executive Chairman. "Both firms, experience ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... Incorporated,(Nasdaq: SPEX ) reported a net loss for the three months ended March 31,2008 ... on the company,s on-going Phase 3 clinical trial,in the use of Naturlose for the treatment ... million and reflected the,start-up costs for the trial., , ... ...
... their 2008 Annual,Meeting, shareholders of Spherix Incorporated (Nasdaq: SPEX ) ... Douglas T. Brown, Senior VP and Manager of Corporate Banking Government ... Cox, Jr., Principal, Asset Protection Company -- Claire L. Kruger, ... Spherix -- Gilbert V. Levin, Ph.D., Director of Science and ...
... Executive Chairman Set Sights on Expanding,Therapeutic Horizons of ... BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May ... joined Fate Therapeutics as,president and CEO and executive ... internationally recognized stem cell scientists,clinicians and investors dedicated ...
Cached Biology Technology:Spherix Reports 1st Quarter Earnings 2Spherix Holds Annual Shareholders Meeting 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... biosensor microchip that could significantly speed up the ... highly sensitive "nanosensors," analyze how proteins bind to ... effectiveness and possible side effects of a potential ... nanosensors can simultaneously and continuously monitor thousands of ...
... oil spill caused social disruption and psychological stress among ... the Exxon Valdez spill and the impacts are likely ... "Just ask the residents of Cordova today whether they ... Ritchie, assistant director for research of the University of ...
... study by researchers at the Virginia Institute of Marine ... does kill large numbers of copepodstiny crustaceans that are ... studyby VIMS graduate student Samantha Bickel, VIMS professor Kam ... the March issue of the Journal of Experimental ...
Cached Biology News:New biosensor microchip could speed up drug development, Stanford researchers say 2New biosensor microchip could speed up drug development, Stanford researchers say 3Gulf oil spill similar to Exxon Valdez in initial social and mental impacts, study finds 2VIMS study: Propeller turbulence may affect marine food webs 2VIMS study: Propeller turbulence may affect marine food webs 3
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Low Speed Shaker ,Product Information ... shaker is a high quality, general purpose shaker ... after the other models in the line, the ... easy-access control panel. Electronic controls are utilized for ...
... a chromogenic medium for the detection, ... (except S. thyphi) and total coliforms ... takes a maximum of 24 hours, ... sterilization during preparation and performs a ...
... ActiveSight, the leading provider of X-ray ... offers fragment-based screening services to its ... involves the binding of drug-like fragments ... protein drug targets, allowing scientists to ...
Biology Products: